Destiny Pharma – Neil Clark, CEO (AIM:DEST) One2One Virtual Forum 10th December 2021

Destiny Pharma PLC (Purpose:DEST) (Destiny Pharma PLC (Purpose:DEST)) is a scientific stage, ground breaking biotechnology firm concentrated on the growth of novel medicines that can stop existence-threatening infections. The firm’s pipeline has novel microbiome-dependent biotherapeutics and XF drug scientific property together with NTCD-M3, a Section 3 ready treatment method for the prevention of C. difficile an infection (CDI) recurrence which is the top cause of medical center obtained infections in the US. Destiny’s pipeline also consists of XF-73 nasal gel, which has a short while ago done a positive Section 2b scientific demo targeting the prevention of submit-surgical staphylococcal medical center infections together with MRSA. The firm is also co-developing SPOR-COV, a novel, biotherapeutic merchandise for the prevention of COVID-19 and other viral respiratory infections.